Abstract
ObjectiveTo compare 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional 111In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs).Materials and MethodsThis was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body 111In-octreotide scintigraphy and whole-body 68Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning.ResultsCompared with 111In-octreotide scintigraphy, 68Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by 68Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion.ConclusionWe conclude that 68Ga-DOTATATE PET/CT is superior to conventional 111In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.
Highlights
Neuroendocrine tumors (NETs) constitute a rare type of tumor, the rate of their detection has beenRadiol Bras. 2022 Jan/Fev;55(1):13–180100-3984 © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem increasing substantially because of the ever greater accuracy of diagnostic modalities
Our data demonstrate the superiority of 68Ga-DOTATATE positron-emission tomography/computed tomography (PET/CT) over 111In-octreotide SSTR scintigraphy (SRS) for the detection of neuroendocrine tumors (NETs)
Most of the findings were concordant between the two methods, 68Ga-DOTATATE PET/CT yielded additional findings that served to indicate changes in the treatment plan in 12.2% of the cases evaluated
Summary
Neuroendocrine tumors (NETs) constitute a rare type of tumor, the rate of their detection has been. 0100-3984 © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem increasing substantially because of the ever greater accuracy of diagnostic modalities. They originate mainly in the gastrointestinal tract or lung tissues and are characterized. Cavicchioli M, et al / 68Ga-DOTATATE PET/CT in neuroendocrine tumors by somatostatin receptor (SSTR) overexpression. Scintigraphy with 111In-radiolabeled somatostatin analogues has proven to be an effective diagnostic imaging method for the detection of well-differentiated NETs. Additional radiotherapy for an intraconal NET Change Class Impact. The 68Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three (7.3%) of the 41 patients. One patient was found to have a second primary thyroid tumor, which was confirmed postoperatively to be Hürthle cell carcinoma; one had bowel nonHodgkin lymphoma, which was confirmed postoperatively; and one had a suspected second primary breast tumor, which was confirmed by percutaneous biopsy to be a metastatic NET
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
